Evidence map›Paper›PMID 24165179›Full record

ArticleAntimicrobial agents and chemotherapy2014

Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon.

Marly M Marques, Monica R F Costa, Franklin S Santana Filho, José L F Vieira, Margareth T S Nascimento, Larissa W Brasil, Fátima Nogueira, Henrique Silveira, Roberto C Reyes-Lecca, Wuelton M Monteiro and 2 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02691910 (Efficacy of Chloroquine), which is not on this map. Cited by 59 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 8 pooled it
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02691910 phase2 / phase3completednot on this map

Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection

TypeinterventionalSponsorOswaldo Cruz FoundationRan2014 to 2015Enrolled204ConditionsMalaria, VivaxArmsChloroquine, Primaquine
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 8 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Investigation of Mutations in theMicroorganisms · 2024
    Article
  14. AreBiomedicines · 2024
    Article
  15. The activity of methylene blue against asexual and sexual stages ofFrontiers in cellular and infection microbiology · 2023
    Article
  16. Oxidative Stress in Malaria: Potential Benefits of Antioxidant Therapy.International journal of molecular sciences · 2022
    Review
  17. Short-Time Recurrences ofInternational journal of environmental research and public health · 2021
    Article
  18. Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions.International journal for parasitology. Drugs and drug resistance · 2021
    Review
  19. Review
  20. An Ultra-Sensitive Technique: UsingPathogens (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Marly M MarquesFundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil.
Monica R F Costa
Franklin S Santana Filho
José L F Vieira
Margareth T S Nascimento
Larissa W Brasil
Fátima Nogueira
Henrique Silveira
Roberto C Reyes-Lecca
Wuelton M Monteiro
Marcus V G Lacerda
Maria G C Alecrim
Universidade do Estado do Amazonas · BRFundação de Medicina Tropical · BRInstituto de Investigação Científica Tropical · PTUniversidade Federal do Pará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on chloroquine (CQ)-resistant Plasmodium vivax in Latin America is limited, even with the current research efforts to sustain an efficient malaria control program in all these countries where P. vivax is endemic and where malaria still is a major public health issue. This study estimated in vivo CQ resistance in patients with uncomplicated P. vivax malaria, with use of CQ and primaquine simultaneously, in the Brazilian Amazon. Of a total of 135 enrolled subjects who accomplished the 28-day follow-up, parasitological failure was observed in 7 (5.2%) patients, in whom plasma CQ and desethylchloroquine (DCQ) concentrations were above 100 ng/dl. Univariate analysis showed that previous exposure to malaria and a higher initial mean parasitemia were associated with resistance but not with age or gender. In the multivariate analysis, only high initial parasitemia remained significant. Hemoglobin levels were similar at the beginning of the follow-up and were not associated with parasitemia. However, at day 3 and day 7, hemoglobin levels were significantly lower in patients presenting CQ resistance. The P. vivax dhfr (pvdhfr), pvmrp1, pvmdr1, and pvdhps gene mutations were not related to resistance in this small sample. P. vivax CQ resistance is already a problem in the Brazilian Amazon, which could be to some extent associated with the simultaneous report of anemia triggered by this parasite, a common complication of the disease in most of the areas of endemicity.

Indexed as

AnemiaAntimalarialsBrazilChloroquineDrug ResistanceFemaleHumansMalaria, VivaxMalePlasmodium vivaxAntimalarialsChloroquinedesethylchloroquine

Identifiers

PMID24165179
PMCPMC3910749
OpenAlexW2084378609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.